In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.
Biopharma Dive, a biopharmaceutical website, recently selected the annual pharmaceutical company (Mersha East), the annual biotechnology company (Spark Therapeutics), the annual CEO (Emma Walmsley, GSK), the annual transaction (Takeda $62 billion acquisition of Shire), the annual innovation (RNA Targeted therapy), an annual new drug (Ajin/Nuohua migraine drug Aimovig). … Continue Reading BioPharma: Six “most” in 2018
Cellular therapies based on effector T cells over the past decade, particularly CAR-T therapy, have revolutionized the treatment of many types of cancer. In 2017, the FDA approved two CAR-T therapies for the treatment of certain types of cancer associated with B cells, and research in the field of… Continue Reading How to apply CAR-T therapy to treat autoimmune diseases?
The future of rindopepimut seems to be bright in 2015. The results of three clinical trials have shown that this peptide tumor therapeutic vaccine can elicit an immune response and delay polymorphic glioblastoma multiforme (GBM). The disease progression of the patient. GBM is the most malignant brain cancer. The… Continue Reading Bronze Age of Glioblastoma Immunotherapy
In 2010, with the support of the international drug purchasing agency UNITAID, the Medicines Patent Pool (MPP) was established in Geneva. MPP negotiates with the original pharmaceutical company on the voluntary license of the drug patent. The original drug company puts its drug patent into the patent pool, and… Continue Reading Medicines Patent Pool: chicken ribs or opportunities?
T cells have always been at the center of tumor immunotherapy. In recent years, CAR-T therapy has shown its power to treat certain types of cancer, and the FDA has approved two CAR-T therapies for the treatment of lymphoma or leukemia. At the same time, there are currently hundreds… Continue Reading How will CAR-NK therapy affect the progress of cell therapy?
For some B-cell-related blood cancers, the efficacy of CAR-T therapy is unquestionable. Last year, the FDA approved two CAR-T therapies, and many pharmaceutical companies began investing a lot of money and manpower in the field. However, the clinical application of CAR-T therapy still faces many obstacles, such as toxicity… Continue Reading New directions for CAR-T treatment: autoimmune disease and graft versus host disease
As the largest organ of the human body, the skin protects the human body from harmful substances from the outside. But because of this, the skin is also the most vulnerable part. Every year, 300,000 people worldwide die from skin wounds. Most of these people die from wounds that… Continue Reading Wound cells transform into stem cells, perfect for repairing wounds
The last July 28th is the 8th World Hepatitis Day. The latest WHO statistics show that chronic hepatitis B and hepatitis C affect approximately 325 million people worldwide, resulting in 1.34 million deaths each year. Nearly 30 million people infected with hepatitis B in China and 7.6 million people infected… Continue Reading Zhimeng Medicine Interview | Can hepatitis B be cured?
According to the US CB Insight database, the total amount of investment in the field of cancer in 2017 exceeded US$1.4 billion. Although it has declined from US$2 billion in 2016, it still accounts for a considerable share of the total VC. The report shows that most of them have… Continue Reading What are the concerns of British investors about cancer?